13F filer · CIK 1738053
VHCP Management III, LLC
New York, NY · filing since Q3 2018 · last filing Feb 13, 2020
Reported value
$503.6M
+$341.6M vs prior
Positions
18
New / sold out
9 / 8
Added / reduced
2 / 5
Turnover
16.9%
buys $264.3M · sells $56.2M
Top-10 weight
90.4%
Biggest buys vs Q3 2019
| Change | Security | Shares change | Change % | Est. trade value |
|---|---|---|---|---|
| Added | Constellation Pharmaceuticals | +2,449,575 | +3674.3% | +$115.4M |
| New | Relmada Therapeutics Inc | +767,938 | – | +$29.9M |
| New | 89Bio Inc | +958,765 | – | +$25.2M |
| New | Forty Seven Inc | +516,381 | – | +$20.3M |
| New | Intra-Cellular Therapies Inc | +575,000 | – | +$19.7M |
| New | Iveric Bio Inc | +1,699,797 | – | +$14.6M |
| New | Adverum Biotechnologies Inc | +946,234 | – | +$10.9M |
| New | Mersana Therapeutics Inc | +1,561,389 | – | +$8.9M |
| New | Myovant Sciences Ltd | +455,255 | – | +$7.1M |
| New | Nextcure Inc | +119,693 | – | +$6.7M |
1 more rows. Subscribe for $29/month to see every row, download the data and use the API.
Biggest sells vs Q3 2019
| Change | Security | Shares change | Change % | Est. trade value |
|---|---|---|---|---|
| Sold out | Ra Pharmaceuticals | -670,350 | -100.0% | $-15.9M |
| Sold out | La Jolla Pharmaceuticals | -1,251,898 | -100.0% | $-11.0M |
| Sold out | BioCryst Pharmaceuticals Inc | -2,708,207 | -100.0% | $-7.8M |
| Reduced | Protagonist Therapeutics Inc | -991,419 | -92.5% | $-7.0M |
| Reduced | Axsome Therapeutics Inc | -63,335 | -3.9% | $-6.5M |
| Sold out | Tricida Inc | -80,348 | -100.0% | $-2.5M |
| Sold out | Kiniksa Pharmaceuticals Ltd | -277,137 | -100.0% | $-2.4M |
| Reduced | Obseva SA | -349,525 | -30.1% | $-1.3M |
| Reduced | Bellerophon Therapeutics | -2,033,272 | -84.1% | $-709.6K |
| Sold out | Radius Health Inc | -23,131 | -100.0% | $-596.0K |
3 more rows. Subscribe for $29/month to see every row, download the data and use the API.
Estimated trade value = change in shares × this quarter's implied price. 13F filings show quarter-end positions, not individual trades.
Reported value by quarter
Holdings · Q4 2019
| # | Security | Shares | Value | Weight |
|---|---|---|---|---|
| 1 | Axsome Therapeutics IncCOM | 1,547,994 | $160.0M | 31.77% |
| 2 | Constellation PharmaceuticalsCOM | 2,516,242 | $118.5M | 23.54% |
| 3 | Milestone Pharmaceuticals IncCOM | 2,066,529 | $33.1M | 6.57% |
| 4 | Relmada Therapeutics IncCOM | 767,938 | $29.9M | 5.95% |
| 5 | 89Bio IncCOM | 958,765 | $25.2M | 5.00% |
| 6 | 10X Genomics Inc.COM | 300,000 | $22.9M | 4.54% |
| 7 | Forty Seven IncCOM | 516,381 | $20.3M | 4.04% |
| 8 | Intra-Cellular Therapies IncCOM | 575,000 | $19.7M | 3.92% |
| 9 | Iveric Bio IncCOM | 1,699,797 | $14.6M | 2.90% |
| 10 | Kalvista PharmaceuticalsCOM | 619,905 | $11.0M | 2.19% |
8 more rows. Subscribe for $29/month to see every row, download the data and use the API.